Tag Archives: roche

Roche and Alnylam Report Topline Ph2 Hypertension Results; ITBMed Initiates Ph2 Siplizumab Study in New Onset T1DM Patients

Two cardiometabolic-related news items have been observed: Roche and Alnylam announced topline results from KARDIA-1, a Ph2 study of zilebesiran for the treatment of hypertension (view press release); and ITBMed initiated a Ph2 exposure-response study evaluating if treatment with siplizumab (TCD601) improves beta-cell function in adults recently diagnosed with T1DM (view CT.gov record). Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Lilly Completes Tirzepatide Obesity Trials; Teladoc, Viking, and Roche Q2 ‘23 Earnings

Four cardiometabolic-related news items have been observed: Lilly announced topline results from SURMOUNT-3 and SURMOUNT-4, demonstrating up to 26.6% mean weight loss (view press release); Teladoc Health (press release; slides), Viking Therapeutics (press release), and Roche (press release; slides) hosted their respective Q2 ‘23 earnings calls. Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Biocon Receives Even More Form 483 Observations; Roche and Alnylam Partner for Hypertension RNAi; Dario Issues Preliminary Q2 ’23 Results and Business Update

Three cardiometabolic-related news items have been observed: Biocon announced FDA conducted two cGMP inspections at Biocon’s insulin manufacturing facility in Malaysia and issued eight Form 483 observations (view press release); Roche and Alnylam announced a strategic agreement to co-develop and co-commercialize zilebesiran for the treatment of hypertension; and Dario announced a new agreement with an undisclosed large regional health plan as well as preliminary Q2 ’23 results (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Medtronic Resolves FDA Warning Letter; HSR Waiting Period for Sanofi’s Provention Bio Acquisition Expires; Roche Q1 ’23 Earnings

Three cardiometabolic-related news items have been observed: Medtronic announced FDA lifted the warning letter issued at its diabetes headquarters in Northridge, CA, in December 2021 (view press release); Sanofi announced the waiting period under the Hart-Scott-Rodino Act of 1976 (HSR Act) for its proposed acquisition of Provention Bio has expired (view press release); and Roche hosted its Q1 ‘23 earnings call (press release; slides). Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Lilly, Merck, and Roche Q4 ’22 Earnings Updates

Three cardiometabolic-related news items have been observed: Lilly (press release; slides), Merck (press release; slides), and Roche (press release; slides) hosted their respective Q4 ’22 earnings calls. Below, FENIX provides highlights and insights from the earnings calls. 

This content is for Read Less members only.
Already a member? Log in here

Roche Diabetes Partners with New Mark Cuban Company

Mark Cuban’s new company, Cost Plus Drugs, announced on Twitter (view tweet here) it has partnered with Roche Diabetes Care USA to provide patients with select Accu-Chek BGM products. Below, FENIX provides highlights and insights about the Cost Plus Drugs and Roche partnership.

This content is for Read Less members only.
Already a member? Log in here

Lannett, Merck, Roche, and BD Q4 ‘21 and FY ’21 Earnings Updates

A series of cardiometabolic-related news items have been observed: Lannett (press release), Merck (press release; slides), Roche (press release; slides), and BD (press release; slides) hosted their respective Q4 ’21 earnings calls. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Already a member? Log in here

JPM 2022 Day 2: LLY, ABT, AMRN, SNY, AMGN, RHHBY, and TEVA

On the second day of JPM 2022, FENIX has provided coverage of presentations by major CVRM companies including Lilly, Abbott, Amarin, Sanofi, Amgen, Roche, and Teva. Below, FENIX provides a topline summary of key takeaways followed by more in-depth coverage

This content is for Read Less members only.
Already a member? Log in here

GSK’s Daprodustat Ph3 Data Positive But Not Entirely Clean; BI/Lilly’s Jardiance Demonstrates Consistent Cardio-Renal Benefits in HF; Novo Announces Positive Ph3b STEP 5 Trial Results; CytoDyn Reports Positive Preliminary Data from Ph2 Leronlimab Trial; Roche and Sanofi Mallya Collaboration; Intuity Medical’s Automatic BGM Available in US; Zealand and DEKA Collaboration for Continuous Infusion Pump

A series of cardiometabolic-related news items have been observed from GSK, BI/Lilly, Novo Nordisk, CytoDyn, Roche, Intuity Medical, and Zealand. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here